-
1.发明申请SIGMA LIGANDS FOR THE PREVENTION AND/OR TREATMENT OF EMESIS INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY 有权用于预防和/或治疗由化疗或放射治疗引起的EMESIS的SIGMA配偶公开(公告)号：US20130109692A1
公开(公告)日：2013-05-02
申请号：US13698718
申请日：2011-05-20
IPC分类号： A61K45/06 , A61K31/5377 , C07D231/22
CPC分类号： A61K45/06 , A61K31/337 , A61K31/4523 , A61K31/4725 , A61K31/475 , A61K31/496 , A61K31/5377 , A61K33/24 , C07D231/22 , A61K2300/00
摘要： The invention refers to the use of a sigma ligand, preferably a sigma ligand of formula (I), to prevent or treat emesis induced by a chemotherapeutic agent or radioactivity, especially emesis induced by taxanes, vinca alkaloids or platin chemotherapeutic drugs.
摘要翻译： 本发明涉及使用Sigma配体，优选式（I）的Sigma配体来预防或治疗由化学治疗剂或放射性引起的呕吐，特别是由紫杉烷，长春花生物碱或铂化学治疗药引起的呕吐。
-
2.发明授权公开(公告)号：US09782483B2
公开(公告)日：2017-10-10
申请号：US13698718
申请日：2011-05-20
IPC分类号： A61K45/06 , C07D231/22 , A61K31/5377 , A61K31/337 , A61K31/4523 , A61K31/4725 , A61K31/475 , A61K31/496 , A61K33/24
CPC分类号： A61K45/06 , A61K31/337 , A61K31/4523 , A61K31/4725 , A61K31/475 , A61K31/496 , A61K31/5377 , A61K33/24 , C07D231/22 , A61K2300/00
摘要： The invention refers to the use of a sigma ligand, preferably a sigma ligand of formula (I), to prevent or treat emesis induced by a chemotherapeutic agent or radioactivity, especially emesis induced by taxanes, vinca alkaloids or platin chemotherapeutic drugs.
-
公开(公告)号：US20090264457A1
公开(公告)日：2009-10-22
申请号：US12221364
申请日：2008-08-01
IPC分类号： A61K31/437 , A61K31/404 , A61K31/426 , A61K31/416 , A61K31/454 , A61P25/00 , A61P25/28
CPC分类号： A61K31/192 , A61K31/4045 , A61K31/4155 , A61K31/428 , A61K31/429 , A61K31/433 , A61K31/4439 , A61K31/454 , A61K31/4709 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/63
摘要： The present invention relates to a Combination of at least two 5HT6-Ligands of which one is a partial or agonist while the other is a full antagonist or an inverse agonist, a medicament comprising this comination, the use of the combiantion in the manufacture of a medicament for the treatment of memory disorders ADHD, and methods of treatment using the combination or its members.
摘要翻译： 本发明涉及至少两种5HT6配体的组合，其中一种是部分或激动剂，另一种是完全拮抗剂或反向激动剂，包含该配体的药物，组合物在制备中的用途 用于治疗记忆障碍ADHD的药物，以及使用该组合或其成员的治疗方法。
-
4.发明申请COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY 审中-公开一种胆碱酯酶抑制剂与一种具有5-HT6受体亲和力的化合物的组合公开(公告)号：US20100120747A1
公开(公告)日：2010-05-13
申请号：US12305516
申请日：2007-06-22
IPC分类号： A61K31/496 , A61K31/536 , A61K31/404 , A61K31/505 , A61K31/44 , A61K31/4439 , A61K31/437 , A61K31/4525 , A61K31/4965 , A61K31/55 , A61P3/00 , A61P25/00 , A61P1/00
CPC分类号： A61K45/06 , A61K31/445 , A61K2300/00
摘要： The present invention relates to an active substance combination comprising at least one compound with 5-HT6 receptor affinity, and at least one cholinesterase inhibitor, a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament.
摘要翻译： 本发明涉及包含至少一种具有5-HT 6受体亲和力的化合物和至少一种胆碱酯酶抑制剂，包含所述活性物质组合的药物以及所述活性物质组合用于制备药物的活性物质组合物 。
-
5.发明申请Combination of NMDA-Receptor Ligand and a Compound With 5-HT6 Receptor Affinity 审中-公开NMDA受体配体与具有5-HT6受体亲和性的化合物的组合公开(公告)号：US20100074955A1
公开(公告)日：2010-03-25
申请号：US12441874
申请日：2007-09-18
CPC分类号： A61K45/06 , A61K31/13 , A61K31/4045 , A61K2300/00
摘要： The present invention relates to an active substance combination comprising at least one compound with 5-HT6 receptor affinity, and at least NMDA-receptor ligand, a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament.
摘要翻译： 本发明涉及包含至少一种具有5-HT 6受体亲和力的化合物和至少NMDA受体配体的活性物质组合物，包含所述活性物质组合的药物，以及所述活性物质组合用于制备 药物。
-
6.发明申请Substituted Indazolyl Sulfonamide and 2,3-Dihydro-Indolyl Sulfonamide Compounds, their Preparation and Use in Medicaments 审中-公开取代的吲唑基磺酰胺和2,3-二氢 - 吲哚基磺酰胺化合物，它们在药物中的制备和用途公开(公告)号：US20090005417A1
公开(公告)日：2009-01-01
申请号：US11813246
申请日：2005-12-29
IPC分类号： A61K31/454 , C07D401/14 , C07D231/56 , A61K31/416 , A61P25/34 , A61P25/28 , A61P1/00 , A61P3/04 , A61P25/24 , A61P25/32 , A61P25/36 , A61K31/429 , C07D513/04
CPC分类号： C07D409/12 , C07D231/56 , C07D401/04 , C07D513/04
摘要： The present invention relates to substituted indazolyl sulfonamide and 2,3-dihydroindolyl sulfonamide compounds of general formula I, a process for their preparation, medicaments comprising said substituted indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds as well as the use of said substituted indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds for the preparation of medicaments, which are particularly suitable for the prophylaxis and/or treatment of disorders or diseases that are at least partially mediated via 5-HT6 receptors.
摘要翻译： 本发明涉及通式I的取代的吲唑基磺酰胺和2,3-二氢吲哚基磺酰胺化合物，其制备方法，包含所述取代的吲唑基磺酰胺和2,3-二氢 - 吲哚基磺酰胺化合物的药物以及使用所述 取代的吲唑基磺酰胺和用于制备药物的2,3-二氢 - 吲哚基磺酰胺化合物，其特别适用于预防和/或治疗至少部分通过5-HT 6受体介导的病症或疾病。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.033 秒)
